This site is intended for healthcare professionals residing in Canada.
Menu
Close
Menu
Close
Recommendations
SOGC Recommendations
NACI Recommendations
CIQ Recommendations
About RSV
About RSV
Infants at Risk
Individuals ≥ 60 Years of Age
About ABRYSVO
Reconstitution and Storage
Dosing and Administration
Mechanism of Action
Efficacy and Safety Profiles
Clinical Trials
MATISSE Study Design
MATISSE Data
MATISSE Safety Profile
RENOIR Study Design
RENOIR Data
RENOIR Safety Profile
More
Coverage Information
Patient Profiles
FAQ
Resources
Study Design
Definitions
Incidence of Symptoms
A Phase 3, multicentre, randomized, double-blind, placebo-controlled global study.
Adapted from the ABRYSVO Product Monograph.1
Primary objective was the assessment of vaccine efficacy in the first RSV season.
RSV: respiratory syncytial virus; RRR: relative risk reduction; LRTD: lower respiratory tract disease; RT-PCR: reverse transcription-polymerase chain reaction
RSV-associated LRTI and ARTI was defined as RT-PCR–confirmed RSV illness with:
RSV: respiratory syncytial virus; RRR: relative risk reduction; LRTD: lower respiratory tract disease; ARTI: acute respiratory tract illness; RT-PCR: reverse transcription-polymerase chain reaction
Adapted from Walsh EE et al. 2023.
Check out the RENOIR trial for more information.
RSV: respiratory syncytial virus; RRR: relative risk reduction; LRTD: lower respiratory tract disease; RT-PCR: reverse transcription-polymerase chain reaction
Find information about ABRYSVO.
Find some additional resources for you and your patients.
To report an adverse event, please call 1-866-723-7111
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
© Pfizer Canada ULC 2024. All rights reserved. The information is intended only for healthcare professionals resident in Canada. ®Pfizer Inc., used under license.